NYSE (USD): Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Last Price
45.04
Today's Change
-0.90 (1.95%)
Day's Change
43.84 - 47.00
Trading Volume
1,698,581
Market Cap
4 Billion
Shares Outstanding
94 Million
Avg Volume
979,541
Avg Price (50 Days)
38.48
Avg Price (200 Days)
42.02
PE Ratio
-4.84
EPS
-9.30
Earnings Announcement
06-Nov-2024
Previous Close
45.94
Open
46.74
Day's Range
43.84 - 47.0
Year Range
17.17 - 62.21
Trading Volume
1,717,899
1 Day Change
-1.96%
5 Day Change
10.66%
1 Month Change
7.93%
3 Month Change
29.65%
6 Month Change
-19.36%
Ytd Change
7.42%
1 Year Change
161.25%
3 Year Change
-66.23%
5 Year Change
0.33%
10 Year Change
157.37%
Max Change
157.37%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.